HFS
SRPT icon

Hantz Financial Services’s Sarepta Therapeutics SRPT Stock Holding History

Hantz Financial Services’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Buy
10,144
+6,642
+190% +$126K ﹤0.01% 1150
2026
Q1 		$76K Buy
3,502
+718
+26% +$13.9K ﹤0.01% 1396
2025
Q4 		$60K Buy
2,784
+2,163
+348% +$45.6K ﹤0.01% 1362
2025
Q3 		$12K Buy
621
+302
+95% +$5.38K ﹤0.01% 1776
2025
Q2 		$5K Buy
319
+242
+314% +$10.3K ﹤0.01% 1767
2025
Q1 		$5K Buy
+77
New +$8.11K ﹤0.01% 1171

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Hantz Financial Services's SRPT Position: Q2 2026 in Review

Hantz Financial Services increased its Sarepta Therapeutics (SRPT) stake by 190% in Q2 2026, buying an estimated $126K and bringing the position to 10,144 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #1150.

Hantz Financial Services first reported a position in SRPT in Q1 2025 and has held it in 6 quarters since. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Hantz Financial Services held 10,144 shares of Sarepta Therapeutics worth $182K as of Q2 2026.
  • Hantz Financial Services bought 6,642 Sarepta Therapeutics shares in Q2 2026, an estimated $126K.
  • Sarepta Therapeutics made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #1150 holding.
  • Hantz Financial Services first reported a position in Sarepta Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.